在LRRK2中α-synuclein基因低甲基化 帕金森病患者 帕金森病患者
Lorena de Mena1,2, Guillem Parés1,2, Alicia Garrido2,3,4
1Laboratory of Parkinson's and Other Movement Disorders, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
Movement disorders : official journal of the Movement Disorder Society
|December 23, 2024
概括
氨酸丰富的重复激酶2 (LRRK2) 驱动的帕金森病 (L2PD) 显示α-Synuclein (SNCA) 基因低甲基化,类似于异常性帕金森病. 这种SNCA的表观遗传变化是L2PD患者的新发现.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 异常性帕金森病 (iPD) 与α-Synuclein (SNCA) 基因低甲基化有关.
- 氨酸丰富的重复激酶2 (LRRK2) 驱动的帕金森病 (L2PD) 与iPD有临床相似之处.
- 由于临床相似性,研究LRRK2队列中的SNCA表观遗传状态至关重要.
研究的目的:
- 为了调查SNCA基因在LRRK2突变载体的西班牙队列中的表观遗传状态.
- 为了比较L2PD患者,非表现载体,iPD患者和健康对照患者之间的SNCA甲基化模式.
主要方法:
- 在SNCA推广地区的23个CpG站点的评估甲基化水平.
- 利用了来自475名受试者的外周血液DNA:151名L2PD患者,55名LRRK2非表现载体,115名iPD患者和154名健康对照.
- 采用了定量甲基化分析技术.
主要成果:
- 与对照组相比,在L2PD患者的23个CpG中的11个 (48%) 中观察到显著的SNCA低甲基化.
- 在IPD患者的23个CPG中的22个发现了广泛的SNCA低甲基化 (96%).
- 无症状的LRRK2突变载体表现出与健康对照相似的SNCA甲基化概况.
结论:
- 这项研究提供了SNCA低甲基化在L2PD患者中的第一个证据.
- 在LRRK2驱动的帕金森病中,SNCA低甲基化是一种潜在的表观遗传生物标志物.
- 建议在不同的全球LRRK2队列进行进一步验证,以证实这些发现.
相关概念视频
Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Parkinson's Disease: Overview
476
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
476
Parkinson's Disease: Treatment
216
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
216


